Stargardt disease – Discover Pharma

Welcome to Discover Pharma! Today is : March 16, 2026

Stargardt disease

Cell & Gene Therapy,Clinical Trials,Drug approval,Rare Diseases,Research & Development
AAVantgarde secures FDA orphan drug designation and UK trial approval for Stargardt gene therapy
AAVantgarde Bio has received two regulatory milestones for its investigational [...]

October 2, 2025
Cell & Gene Therapy,Rare Diseases,Regulatory Affairs
AAVB-039 Gains FDA clearance to advance treatment for Stargardt Disease
AAVantgarde’s AAVB-039 gene therapy, targeting the root cause of Stargardt [...]

July 17, 2025
Cell & Gene Therapy,Clinical Trials,Movers & Shakers,Rare Diseases
Ascidian boosts RNA therapy push with key hire and expert board for Stargardt trial
Ascidian Therapeutics has appointed Murray Abramson as chief development officer. [...]

June 30, 2025
CDMOs & Manufacturing,Cell & Gene Therapy,Partnerships & Funding
SpliceBio secures $135 Million series B to advance dual-AAV therapy for Stargardt Disease
Funding will support clinical development of SB-007 and expand pipeline [...]

June 11, 2025

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK